ArticleJournal of muscle research and cell motility2026
The role of melatonin in attenuation of vascular endothelin-1 reactivity via calcium channels and endothelial derived relaxing factors in STZ-induced diabetic aortic rats.
Article in Journal of muscle research and cell motility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus can apply its first adverse effects by developing endothelial dysfunction, which can progress to diabetic vasculopathy. This study was assessed the influence of melatonin on aortic reactivity to endothelin-1 (ET-1) in streptozotocin (STZ)-induced diabetic rats and to identify its mechanisms through calcium channels and endothelium-derived relaxing factors (EDRFs). This experimental study was carried out on rats randomly assigned to three groups: control, diabetic (induced by a single intraperitoneal dose of STZ), and diabetic treated with melatonin (30 mg/kg for two weeks). After the rats were anesthetized and aortic rings were prepared, concentration-response curves to ET-1 were recorded alone and following preincubation with amlodipine (L-type calcium channel blocker), L-NAME (NOS inhibitor), and indomethacin (COX inhibitor). Histomorphic changes evaluated in all groups. Melatonin reduced vascular reactivity to ET-1 in the aorta of diabetic rats. Amlodipine did not reduce ET-1–induced contraction in diabetic group, but in the melatonin group, the inhibitory effect of amlodipine was restored (P < 0.05). Pretreatment with L-NAME decreased the induced contraction in diabetic rats, unlike in the control group. Melatonin led to a contraction response close to that of the control group in diabetic rats. Diabetes increased aortic wall thickness and perinuclear space, and melatonin reversed these changes (P < 0.05). The findings indicate that melatonin reduces vascular dysfunction and structural damage in diabetes by restoring L-type calcium channel sensitivity and modulating the balance of EDRFs, such as NO and prostanoids. These results highlight the potential of melatonin as an adjunct therapy for preventing diabetic vascular complications.
Indexed as
Identifiers
42020644What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.